Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 studySylvie Castaigné, Hervé Dombret, Oumédaly Reman et al.|The Lancet|2012Cited by 994
Gemtuzumab ozogamicin for <i>de novo</i> acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trialJuliette Lambert, Sylvie Castaigné, Cécile Pautas et al.|Haematologica|2018Cited by 349
Drug-resistant cytomegalovirus in transplant recipients: a French cohort studySébastien Hantz, Alexandra Ducancelle, F. Garnier-Geoffroy et al.|Journal of Antimicrobial Chemotherapy|2010Cited by 163
Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22 <sup>+</sup> Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic LeukemiaJean‐Baptiste Robin, Thibaut Leguay, Marc Delord et al.|Journal of Clinical Oncology|2024Cited by 33
Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemiaYves Chalandon, Hervé Dombret, Philippe Rousselot et al.|Blood|2024Cited by 28